ADIPOQ and hepatocellular carcinoma: Here, we developed a model including age, gender, PIVKA-II, GPC-3 and adiponectin that showed a high diagnostic accuracy in cross-validation (AUC = 0.948) for the detection of HCC in patients with dysmetabolic liver disease; the model allowed to correctly identify 87% of the patients included in the study.